#China #Shanghai #Antengene #Autoimmune Diseases #ATG-207

Antengene Reveals Latest Preclinical Results of ATG-207 at ACR 2026

Antengene Corporation Limited, a prominent player in the biotech industry, is making waves with the upcoming presentation of its latest preclinical findings on ATG-207 during the 2026 American College of Rheumatology (ACR) Annual Meeting. This innovative therapy, designed for treating T cell-mediated autoimmune diseases, underscores Antengene's commitment to developing first-in-class medicines.

Background on Antengene and ATG-207

Antengene, headquartered in Shanghai and listed on the Hong Kong Stock Exchange, focuses on groundbreaking therapies aimed at significant unmet medical needs in the treatment of autoimmune diseases, solid tumors, and hematological malignancies. At the forefront of their research is ATG-207, a bifunctional fusion protein that cleverly combines αCD3 and TGF-β to target and regulate the immune response.

While autoimmune diseases often stem from dysregulation within the immune system—characterized by uncontrolled effector T cell activity combating regulatory T cell function—ATG-207 aims to restore this balance. The therapy manipulates the TGF-β signaling pathway, significantly enhancing regulatory T cell (Treg) induction while minimizing potential safety concerns attributed to broad receptor engagement.

Details of the Upcoming Presentation

The poster presentation, titled "Preclinical Characterization of ATG-207, a Masked and TGFβRIII-Biased αCD3-TGF-β Bi-specific Fusion Protein, for the Treatment of T Cell-related Autoimmune Diseases," will take place on November 9, 2026, from 10:30 AM to 12:30 PM Eastern Time. The session falls under Poster Session B, focusing on T Cell Biology and targets in autoimmune and inflammatory diseases.

Key Insights from Preclinical Research

Antengene's rigorous preclinical studies reveal substantial benefits of ATG-207:

• - Binding Preferences and Affinity: ATG-207 exhibits a binding preference for TGFβRIII, demonstrating a notable affinity of 2.42E-06M while avoiding TGFβRII binding entirely. This selectivity suggests a targeted approach, minimizing off-target effects.
• - Cytokine Modulation: The therapy is designed to reduce proinflammatory cytokine production significantly compared to the baseline reactions observed with standard anti-CD3 antibodies, providing a tailored inflammatory response.
• - In vivo Efficacy: In various murine models, such as the experimental autoimmune encephalomyelitis (EAE) model and collagen-induced arthritis (CIA), ATG-207 displayed excellent therapeutic efficacy, promoting Treg induction and mitigating symptoms associated with autoimmune responses.
• - Safety Profile: Safety evaluations conducted in humanized mouse models suggest that ATG-207 is well-tolerated, with promising results during a repeat-dose toxicology study.

This multi-faceted approach demonstrates the potential of ATG-207 to re-establish immune homeostasis, effectively restoring durable immune tolerance in T cell-mediated autoimmune conditions. It marks a significant leap forward in biopharmaceutical sciences that could alter how these diseases are treated.

Conclusion

With the ACR 2026 looming, Antengene's findings set the stage for a vital dialogue around innovative treatments for autoimmune diseases. By focusing on TGF-β signaling in a manner that prioritizes safety and effectiveness, ATG-207 may represent a new frontier in therapeutic strategies aimed at long-lasting immune tolerance restoration. Antengene continues to champion the development of therapies that answer unmet medical needs through innovative solutions.

The ACR 2026 Annual Meeting provides an exciting platform for Antengene to share these critical insights with world-leading rheumatology experts, paving the way for future advancements in the treatment landscape of T cell-mediated autoimmune diseases.